Pulmatrix secures FDA approval for Pulmazole phase 2 clinical study
Pulmazole phase 2 clinical study : Pulmatrix said that the US Food and Drug Administration (FDA) has authorized the Massachusetts-based
Continue readingLatest Pharma Industry News
-
Fresenius Kabi launches Methocarbamol Injection, USP in US
- Novus Therapeutics begins phase 1 trial of OP0201 in otitis media
-
Takeda bags ADCETRIS EC approval for CD30+ Stage IV Hodgkin lymphoma
-
Dr. Henry’s Vitamins introduces Prenatal Plus and Omega-3 for Women
- Samsung Bioepis, C-Bridge Capital collaborate to develop and commercialize biosimilars in China
-
Ablynx wins Cablivi FDA approval for rare blood clotting disorder
- Pulmatrix secures FDA approval for Pulmazole phase 2 clinical study
-
GSK wraps up $5.1bn acquisition of US cancer drug company Tesaro
- BridgeBio Pharma raises $299m to develop genetic disease drugs
- Newron completes patient enrollment for STARS clinical trial of sarizotan
Business News Today
- BAE Systems wins US Army contract for Holston Army Ammunition Plant modernization
- AGS wraps up $49m acquisition of Integrity Gaming
- KKR closes $510m equity investment in Ramky Enviro Engineers
- ADNOC to offload 35% stake in ADNOC Refining to Eni and OMV for $5.8bn
- Dr. Henry’s Vitamins introduces Prenatal Plus and Omega-3 for Women
- Samsung Bioepis, C-Bridge Capital collaborate to develop and commercialize biosimilars in China
- Ablynx wins Cablivi FDA approval for rare blood clotting disorder
- Pulmatrix secures FDA approval for Pulmazole phase 2 clinical study
- Mount Franklin Foods to build new candy manufacturing facility in Mexico
- GSK wraps up $5.1bn acquisition of US cancer drug company Tesaro
